Varanasi News Magazine

Hypertension Pipeline Insight 2023 – Clinical trials, FDA, EMA, and PMDA Approvals, Therapeutic Analysis, Drugs Analysis, and Companies by DelveInsight

 Breaking News
  • No posts were found

Hypertension Pipeline Insight 2023 – Clinical trials, FDA, EMA, and PMDA Approvals, Therapeutic Analysis, Drugs Analysis, and Companies by DelveInsight

January 11
19:20 2023
Hypertension Pipeline Insight 2023 - Clinical trials, FDA, EMA, and PMDA Approvals, Therapeutic Analysis, Drugs Analysis, and Companies by DelveInsight
Hypertension Pipeline

Hypertension pipeline constitutes 100+ key companies continuously working towards developing 100+ Hypertension treatment therapies, analyzes DelveInsight

 

Hypertension (HTN) is systolic blood pressure (SBP) values of 130mmHg or more and/or diastolic blood pressure (DBP) more than 80 mmHg. Hypertension ranks among the most common chronic medical conditions characterized by a persistent elevation in the arterial pressure.

Hypertension has been among the most studied topics of the previous century and has been one of the most significant comorbidities contributing to the development of stroke, myocardial infarction, heart failure, and renal failure.

 

“Hypertension Pipeline Insight, 2023” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hypertension Market.

The Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

 

 

Click here to know more about Hypertension Pipeline Insight Report offering: Hypertension Pipeline Insight

 

DelveInsight’s Hypertension Report covers around 100+ products under different phases of clinical development like

  • Late-stage Hypertension products (Phase III)
  • Mid-stage Hypertension products (Phase II)
  • Early-stage Hypertension product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Hypertension Route of Administration

 

Emerging Hypertension Drugs Under Different Phases of Clinical Development Include:

  • Firibastat: Quantum Genomics
  • Baxdrostat (CIN-107): CinCor Pharma
  • MLS-101: Minerals Therapeutics
  • Zilebesiran (ALN-AGT): Alnylam Therapeutics
  • IONIS-AGT-LRx:Ionis Pharmaceuticals
  • And Others

 

Further Hypertension product details are provided in the report. Download the Hypertension pipeline report to learn more about the emerging Hypertension therapies at: Hypertension Therapeutic Assessment

 

Hypertension Pipeline Analysis

The Hypertension report provides insights into:

  • The report provides detailed insights about companies that are developing therapies for the treatment of Hypertension with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for the Hypertension Treatment.
  • Hypertension companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hypertension market.
  • The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Request for Sample PDF Report for Hypertension pipeline assessment @ Hypertension Treatment Market

 

Key companies in the Hypertension Therapeutics Market:

Some of the Hypertension companies working in the market are Quantum Genomics, CinCor Pharma, Minerals Therapeutics, Alnylam Therapeutics, Ionis Pharmaceuticals, Future Medicine, Pharmosa BioPharm, Aerovate Therapeutics, Novartis, Cereno Scientific AB, Torrent Pharmaceuticals Limited, JeniVision,Inc., Merck Sharp & Dohme LLC, AbbVie, Acceleron Pharma Inc., Hanmi Pharmaceutical Company Limited, Gossamer Bio Inc.,Shanghai Pharmaceuticals Holding Co.Ltd, Insmed Incorporated, Gmax Biopharm LLC., Altavant Sciences GmbH, Bayer, Respira Therapeutics Inc., Aadi Bioscience Inc., Boehringer Ingelheim, JW Pharmaceutical, PRM Pharma,LLC, pH Pharma, Nicox Ophthalmics,Inc., Ocular Therapeutix,Inc., Santen SAS, Whitecap Biosciences,LLC, Chong Kun Dang Pharmaceutical, AJU Pharm Co..Ltd., Laboratoires Thea, Aerami Therapeutics, KBP Biosciences, Cumberland Pharmaceuticals, Vigonvita Life Sciences, IIDong Pharmaceutical Co Ltd, Qlaris Bio Inc and others.

 

Click here to know more about Hypertension Pipeline Insight Report offering: Hypertension Pipeline Insight

 

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Hypertension Current Treatment Patterns

4. Hypertension – DelveInsight’s Analytical Perspective

5. Hypertension Therapeutic Assessment

6. Hypertension Late Stage Products (Phase-III)

7. Hypertension Mid-Stage Products (Phase-II)

8. Hypertension Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Hypertension Products

11. Dormant Hypertension Products

12. Hypertension Discontinued Products

13. Hypertension Product Profiles

14. Key Companies in the Hypertension Market

15. Key Products in the Hypertension Therapeutics Segment

16. Dormant and Discontinued Products

17. Hypertension Unmet Needs

18. Hypertension Future Perspectives

19. Hypertension Analyst Review

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Click here to know more about Hypertension drugs and therapies: Hypertension Clinical Trials

 

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting